» Articles » PMID: 36572740

Assessment of Perfusion Deficit with Early Phases of [F]PI-2620 Tau-PET Versus [F]flutemetamol-amyloid-PET Recordings

Abstract

Purpose: Characteristic features of amyloid-PET (A), tau-PET (T), and FDG-PET (N) can serve for the A/T/N classification of neurodegenerative diseases. Recent studies showed that the early, perfusion-weighted phases of amyloid- or tau-PET recordings serve to detect cerebrometabolic deficits equally to FDG-PET, therefore providing a surrogate of neuronal injury. As such, two channels of diagnostic information can be obtained in the setting of a single PET scan. However, there has hitherto been no comparison of early-phase amyloid- and tau-PET as surrogates for deficits in perfusion/metabolism. Therefore, we undertook to compare [F]flutemetamol-amyloid-PET and [F]PI-2620 tau-PET as "one-stop shop" dual purpose tracers for the detection of neurodegenerative disease.

Methods: We obtained early-phase PET recordings with [F]PI-2620 (0.5-2.5 min p.i.) and [F]flutemetamol (0-10 min p.i.) in 64 patients with suspected neurodegenerative disease. We contrasted global mean normalized images (SUVr) in the patients with a normal cohort of 15 volunteers without evidence of increased pathology to β-amyloid- and tau-PET examinations. Regional group differences of tracer uptake (z-scores) of 246 Brainnetome volumes of interest were calculated for both tracers, and the correlations of the z-scores were evaluated using Pearson's correlation coefficient. Lobar compartments, regions with significant neuronal injury (z-scores <  - 3), and patients with different neurodegenerative disease entities (e.g., Alzheimer's disease or 4R-tauopathies) served for subgroup analysis. Additionally, we used partial regression to correlate regional perfusion alterations with clinical scores in cognition tests.

Results: The z-scores of perfusion-weighted images of both tracers showed high correlations across the brain, especially in the frontal and parietal lobes, which were the brain regions with pronounced perfusion deficit in the patient group (R = 0.83 ± 0.08; range, 0.61-0.95). Z-scores of individual patients correlated well by region (R = 0.57 ± 0.15; range, 0.16-0.90), notably when significant perfusion deficits were present (R = 0.66 ± 0.15; range, 0.28-0.90).

Conclusion: The early perfusion phases of [F]PI-2620 tau- and [F]flutemetamol-amyloid-PET are roughly equivalent indices of perfusion defect indicative of regional and lobar neuronal injury in patients with various neurodegenerative diseases. As such, either tracer may serve for two diagnostic channels by assessment of amyloid/tau status and neuronal activity.

Citing Articles

Correlation of early-phase β-amyloid positron-emission-tomography and neuropsychological testing in patients with Alzheimer's disease.

Volter F, Eckenweber S, Scheifele M, Eckenweber F, Hirsch F, Franzmeier N Eur J Nucl Med Mol Imaging. 2025; .

PMID: 40019578 DOI: 10.1007/s00259-025-07175-5.


Neuronal and oligodendroglial, but not astroglial, tau translates to in vivo tau PET signals in individuals with primary tauopathies.

Slemann L, Gnorich J, Hummel S, Bartos L, Klaus C, Kling A Acta Neuropathol. 2024; 148(1):70.

PMID: 39580770 PMC: 11586312. DOI: 10.1007/s00401-024-02834-7.


A framework for translating tauopathy therapeutics: Drug discovery to clinical trials.

Feldman H, Cummings J, Boxer A, Staffaroni A, Knopman D, Sukoff Rizzo S Alzheimers Dement. 2024; 20(11):8129-8152.

PMID: 39316411 PMC: 11567863. DOI: 10.1002/alz.14250.


Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies.

Dilcher R, Wall S, Gross M, Katzdobler S, Wagemann O, Palleis C Alzheimers Dement. 2024; 20(10):6896-6909.

PMID: 39263969 PMC: 11485081. DOI: 10.1002/alz.14185.


Exploratory Tau PET/CT with [11C]PBB3 in Patients with Suspected Alzheimer's Disease and Frontotemporal Lobar Degeneration: A Pilot Study on Correlation with PET Imaging and Cerebrospinal Fluid Biomarkers.

Strobel J, Yousefzadeh-Nowshahr E, Deininger K, Bohn K, von Arnim C, Otto M Biomedicines. 2024; 12(7).

PMID: 39062033 PMC: 11274645. DOI: 10.3390/biomedicines12071460.


References
1.
Fillit H, Green A . Aducanumab and the FDA - where are we now?. Nat Rev Neurol. 2021; 17(3):129-130. DOI: 10.1038/s41582-020-00454-9. View

2.
Lowe S, Duggan Evans C, Shcherbinin S, Cheng Y, Willis B, Gueorguieva I . Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. J Prev Alzheimers Dis. 2021; 8(4):414-424. DOI: 10.14283/jpad.2021.56. View

3.
Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Forster S . Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2013; 12(3):233-43. PMC: 4986921. DOI: 10.1016/S1474-4422(13)70014-0. View

4.
Tzimopoulou S, Cunningham V, Nichols T, Searle G, Bird N, Mistry P . A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimers Dis. 2010; 22(4):1241-56. DOI: 10.3233/JAD-2010-100939. View

5.
Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View